When high dose may kill cancer cells better in a short term, high dose will increase the possibility to generate bortezomib resistance, suggesting that in addition to p53 status-associated survivin expression, other factors, such as other protein members in the IAP and Bcl-2 families may also play important roles in bortezomib resistance. Here, BCL2 is linked to cancer.